Genetic determinants of response to cardiovascular drugs.

ABSTRACT:

Purpose of review

To survey genetic variation contributing to variable responsiveness and toxicity to important cardiovascular drugs and highlight recent developments in the field of cardiovascular pharmacogenomics and personalized medicine.

Recent findings

Previously recognized pharmacogenomic associations with drug efficacy have been further validated (e.g. with clopidogrel and warfarin) and shown to influence clinically important outcomes. The clinical significance of variants modulating toxicity (e.g. SLCO1B1 with simvastatin) has also been confirmed. The genetic contribution to variable efficacy and toxicity of other important classes of cardiovascular drugs, such as beta-blockers, is becoming increasingly recognized. Prospective trials testing whether the use of genomi

SUBMITTER: Wells QS 

PROVIDER: S-EPMC3874723 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature